Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Kewen Jauss

Hematology & Oncology Little Rock, AR Medical Doctor

NPI 1609984368 CMS profile 466119

8901 Carti Way, Little Rock, AR 72205

Open in the dashboard

General payments

$335

12 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Kewen Jauss of Little Rock, AR is reported in the CMS Open Payments database as having received $335 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 22nd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $137 4
2023 General $25 1
2022 General $26 2
2021 General $35 3
2019 General $112 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kewen Jauss
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Kewen Jauss were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Kewen Jauss Hematology & Oncology median Middle half National median
2019 $112 $529 $121–$2,516 $163
2020 $0 $339 $82–$2,213 $114
2021 $35 $263 $49–$1,965 $132
2022 $26 $416 $103–$2,395 $149
2023 $25 $542 $125–$2,646 $160
2024 $137 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Janssen Biotech, Inc. $115 2 payments
  2. Intuitive Surgical, Inc. $77 1 payment
  3. AstraZeneca Pharmaceuticals LP $39 2 payments
  4. Acrotech Biopharma LLC $26 2 payments
  5. Pfizer Inc. $25 1 payment
  6. Epizyme, Inc., $23 2 payments
  7. Merck Sharp & Dohme Corporation $18 1 payment
  8. Gilead Sciences, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Education $241 10 payments
  2. Food and Beverage $93 2 payments
Products named General payments · program years 2019–2024
  1. IMBRUVICA $99 1 payment
  2. Da Vinci Surgical System $77 1 payment
  3. ENHERTU $26 1 payment
  4. BELEODAQ $26 2 payments
  5. IBRANCE $25 1 payment
  6. TAZVERIK $23 2 payments
  7. WELIREG $18 1 payment
  8. CARVYKTI $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

2,384

Median for Hematology-Oncology: 604

Drug cost

$5,167,900

Median for Hematology-Oncology: $1,306,514

Branded share of claims

38.8%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Verzenio Abemaciclib Brand 78 $1,174,227
Cabometyx Cabozantinib S-Malate Brand 30 $755,116
Neulasta Onpro Pegfilgrastim Brand 104 $707,327
Jakafi Ruxolitinib Phosphate Brand 23 $385,719
Keytruda Pembrolizumab Brand 32 $364,337
Phesgo Pertuzumab-Trastuzumab-Hy-Zzxf Brand 29 $244,800
Imbruvica Ibrutinib Brand 12 $191,968
Ibrance Palbociclib Brand 12 $190,875
Darzalex Faspro Daratumumab-Hyaluronidase-Fihj Brand 19 $187,422
Lanreotide Acetate Generic 18 $149,694

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 222 billing codes

Paid by Medicare

$5,712,633

Of which drugs: $5,082,094

Medicare patients

1,125

Average age 75

Services billed

325,864

695 women, 430 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 51%
Arthritis 48%
Ischemic heart disease 40%
Diabetes 34%
Chronic kidney disease 34%
Depression 28%
COPD 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 44 32,200 $1,439,681
Injection, luspatercept-aamt, 0.25 mg J0896 Office 13 16,200 $512,592
Injection, nivolumab, 1 mg J9299 Office 12 11,140 $273,435
Injection, denosumab, 1 mg J0897 Office 49 10,500 $210,118
Injection, ferric derisomaltose, 10 mg J1437 Office 75 8,600 $137,104
Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg Q5129 Office 12 2,010 $100,696
Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 Office 89 14,350 $90,061
Injection, aprepitant, 1 mg J0185 Office 29 13,000 $17,373
Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram Q5125 Office 22 28,980 $10,856
Injection, decitabine, 1 mg J0894 Office 12 3,550 $4,474

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • AstraZeneca Pharmaceuticals LP $26
$26 — —
WELIREG
  • Merck Sharp & Dohme Corporation $18
$18 — —
CARVYKTI
  • Janssen Biotech, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record